Intravesical BCG instillation after bladder tumor resection is the standard treatment for non-muscle invasive bladder cancer; however, it is not always effective and frequently has undesirable side effects. Therefore, new strategies that improve the clinical management of patients are urgently needed. This study aimed to comprehensively evaluate the bladder tumor immune microenvironment profile after intravesical treatment with a panel of mycobacteria with variation in their cell envelope composition and its impact on survival using an orthotopic murine model to identify more effective and safer therapeutic strategies. tumor-bearing mice were intravesically treated with a panel of BCG and M. brumae cultured under different conditions. Untre...
Bacillus Calmette-Guérin (BCG) instillations for the treatment of non-muscle-invasive bladder cancer...
Copyright © 2019 Rodriguez, Goulart, Pagliarone, Silva, Cunegundes, Nascimento, Borra, Dias, Tagliab...
Preclinical data shows that intravesical instillation of Ty21a/Vivotif®, a commercial vaccine agains...
The standard treatment for high-risk non-muscle invasive bladder cancer (BC) is the intravesical adm...
The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder ...
Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); howeve...
Background Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMI...
Abstract Bacillus Calmette-Guerin (BCG) is the only FDA approved first line therapy for patients wit...
Non-muscle-invasive bladder cancer (NMIBC) is a highly recurrent tumor despite intravesical immunoth...
<div><p>Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent ...
Intravesical Mycobacterium bovis Bacillus Calmette-Guérin (BCG) immunotherapy remains the gold-stand...
Abstract Background Intravesical Bacillus Calmette-Guerin (BCG) is an effective treatment for bladde...
Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent progress...
Non-muscle-invasive bladder cancer (NMIBC) is a highly recurrent tumor despite intravesical immunoth...
Bladder cancer is the 4th to 10th most common cancer worldwide, with non-muscle invasive bladder can...
Bacillus Calmette-Guérin (BCG) instillations for the treatment of non-muscle-invasive bladder cancer...
Copyright © 2019 Rodriguez, Goulart, Pagliarone, Silva, Cunegundes, Nascimento, Borra, Dias, Tagliab...
Preclinical data shows that intravesical instillation of Ty21a/Vivotif®, a commercial vaccine agains...
The standard treatment for high-risk non-muscle invasive bladder cancer (BC) is the intravesical adm...
The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder ...
Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); howeve...
Background Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMI...
Abstract Bacillus Calmette-Guerin (BCG) is the only FDA approved first line therapy for patients wit...
Non-muscle-invasive bladder cancer (NMIBC) is a highly recurrent tumor despite intravesical immunoth...
<div><p>Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent ...
Intravesical Mycobacterium bovis Bacillus Calmette-Guérin (BCG) immunotherapy remains the gold-stand...
Abstract Background Intravesical Bacillus Calmette-Guerin (BCG) is an effective treatment for bladde...
Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent progress...
Non-muscle-invasive bladder cancer (NMIBC) is a highly recurrent tumor despite intravesical immunoth...
Bladder cancer is the 4th to 10th most common cancer worldwide, with non-muscle invasive bladder can...
Bacillus Calmette-Guérin (BCG) instillations for the treatment of non-muscle-invasive bladder cancer...
Copyright © 2019 Rodriguez, Goulart, Pagliarone, Silva, Cunegundes, Nascimento, Borra, Dias, Tagliab...
Preclinical data shows that intravesical instillation of Ty21a/Vivotif®, a commercial vaccine agains...